An Investigator Initiated, Prospective, Randomized, Controlled Study in Order to Evaluate the Effect of Anti-thymocyte Globulin (Fresenius ATG) on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical Allogeneic Hematopoietic Stem-cell Transplantation
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Day of day of neutrophil engraftment (ANC>0.5x10^9/L)
30 days
Yes
Michael Y Shapira, MD
Principal Investigator
Hadassah Medical Organization
Israel: Israeli Health Ministry Pharmaceutical Administration
MYS-06-HMO-CTIL
NCT00616954
May 2008
September 2010
Name | Location |
---|